01 enero 2016

JACC: CARDIOVASCULAR INTERVENTIONS. Transcatheter Versus Surgical Closure of Atrial Septal Defects in Children. A Value Comparison

Yinn Khurn Ooi, MD∗,†; Michael Kelleman, MSPH†; Alexandra Ehrlich, MPH∗; Michelle Glanville, MBA, MHA∗; Arlene Porter, MSN∗; Dennis Kim, MD, PhD∗,†; Brian Kogon, MD∗,†; Matthew E. Oster, MD, MPH∗,†

Objectives: The purpose of this study was to determine whether a transcatheter procedure or surgical closure offers a better value proposition for atrial septal defect (ASD) closure.

01 enero 2016

JACC: CARDIOVASCULAR INTERVENTIONS. Prevention of Contrast-Induced Nephropathy by Central Venous Pressure–Guided Fluid Administration in Chronic Kidney Disease and Congestive Heart Failure Patients

Geng Qian, MD; Zhenhong Fu, MD; Jun Guo, MD; Feng Cao, MD; Yundai Chen, MD

Objectives: This study aimed to explore the hemodynamic index–guided hydration method for patients with congestive heart failure (CHF) and chronic kidney disease (CKD) to reduce the risk of contrast-induced nephropathy (CIN) and at the same time to avoid the acute heart failure.

01 enero 2016

JACC: CARDIOVASCULAR INTERVENTIONS. Late False Aneurysm Formation After Transfemoral TAVR

Colin Schamroth, MBBCh, MMed

An 82-year old women presented with a non–ST-segment elevation myocardial infarction. She had undergone coronary bypass surgery 25 years earlier, and a transcatheter aortic valve replacement (TAVR) 28 months previously.

01 enero 2016

JACC: CARDIOVASCULAR INTERVENTIONS. Development and Validation of a Novel Scoring System for Predicting Technical Success of Chronic Total Occlusion Percutaneous Coronary Interventions. The PROGRESS CTO (Prospective Global Registry for the Study of Chronic Total Occlusion Intervention) Score

Georgios Christopoulos, MD∗; David E. Kandzari, MD†; Robert W. Yeh, MD, MBA‡; Farouc A. Jaffer, MD, PhD‡; Dimitri Karmpaliotis, MD§; Michael R. Wyman, MD‖; Khaldoon Alaswad, MD¶; William Lombardi, MD#; J. Aaron Grantham, MD∗∗; Jeffrey Moses, MD§; Georgios Christakopoulos, MD∗; Muhammad Nauman J. Tarar, MD∗; Bavana V. Rangan, BDS, MPH∗; Nicholas Lembo, MD†; Santiago Garcia, MD††; Daisha Cipher, PhD‡‡; Craig A. Thompson, MD, MMSc§§; Subhash Banerjee, MD∗; Emmanouil S. Brilakis, MD, PhD∗

Objectives: This study sought to develop a novel parsimonious score for predicting technical success of chronic total occlusion (CTO) percutaneous coronary intervention (PCI) performed using the hybrid approach.

01 enero 2016

JACC: CARDIOVASCULAR INTERVENTIONS. Scaffold Thrombosis After Percutaneous Coronary Intervention With ABSORB Bioresorbable Vascular Scaffold. A Systematic Review and Meta-Analysis

Michael J. Lipinski, MD, PhD; Ricardo O. Escarcega, MD; Nevin C. Baker, DO; Hadiya A. Benn; Michael A. Gaglia, Jr., MD, MSc; Rebecca Torguson, MPH; Ron Waksman, MD

Objectives: The aim of this study was to determine the risk of scaffold thrombosis (ST) after percutaneous coronary intervention (PCI) with placement of an ABSORB bioresorbable vascular scaffold (BVS) (Abbott Vascular, Santa Clara, California) by conducting a systematic review and meta-analysis.

01 enero 2016

JACC: CARDIOVASCULAR INTERVENTIONS. Effect of Chronic Kidney Disease in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. A Patient-Level Pooled Analysis of Randomized Controlled Trials

Usman Baber, MD, MSc∗; Gennaro Giustino, MD∗; Samantha Sartori, PhD∗; Melissa Aquino, MSc∗; Giulio G. Stefanini, MD†; P. Gabriel Steg, MD‡; Stephan Windecker, MD, PhD§; Martin B. Leon, MD‖; William Wijns, MD, PhD¶; Patrick W. Serruys, MD, PhD#; Marco Valgimigli, MD, PhD∗∗; Gregg W. Stone, MD‖; George D. Dangas, MD, PhD∗; Marie-Claude Morice, MD††; Edoardo Camenzind, MD‡‡; Giora Weisz, MD#; Pieter C. Smits, MD, PhD§§; David Kandzari, MD‖‖; Clemens Von Birgelen, MD¶¶; Ioannis Mastoris, MD∗; Soren Galatius, MD##; Raban V. Jeger, MD∗∗∗; Takeshi Kimura, MD†††; Ghada W. Mikhail, MD‡‡‡; Dipti Itchhaporia, MD§§§; Laxmi Mehta, MD‖‖‖; Rebecca Ortega, MD¶¶¶; Hyo-Soo Kim, MD###; Adnan Kastrati, MD∗∗∗∗; Alaide Chieffo, MD††††; Roxana Mehran, MD∗

Objectives: This study sought to evaluate: 1) the effect of impaired renal function on long-term clinical outcomes in women undergoing percutaneous coronary intervention (PCI) with drug-eluting stent (DES); and 2) the safety and efficacy of new-generation compared with early-generation DES in women with chronic kidney disease (CKD).

01 enero 2016

JACC: CARDIOVASCULAR INTERVENTIONS. A Randomized Comparison of Reservoir-Based Polymer-Free Amphilimus-Eluting Stents Versus Everolimus-Eluting Stents With Durable Polymer in Patients With Diabetes Mellitus. The RESERVOIR Clinical Trial

Rafael Romaguera, MD∗; Joan A. Gómez-Hospital, MD, PhD∗; Josep Gomez-Lara, MD, PhD∗; Salvatore Brugaletta, MD, PhD†; Eduardo Pinar, MD‡; Pilar Jiménez-Quevedo, MD§; Montserrat Gracida, MD∗; Gerard Roura, MD∗; Jose L. Ferreiro, MD∗; Luis Teruel, MD∗; Eduard Montanya, MD, PhD‖; Antonio Fernandez-Ortiz, MD§; Fernando Alfonso, MD, PhD¶; Marco Valgimigli, MD#; Manel Sabate, MD, PhD†; Angel Cequier, MD, PhD∗

Objectives: The aim of this study was to compare the efficacy of amphilimus-eluting stents (AES) with that of everolimus-eluting stents (EES) in patients with diabetes mellitus (DM).

01 enero 2016

JACC: CARDIOVASCULAR INTERVENTIONS. Polymer-Free Biolimus A9-Coated Stents in the Treatment of De Novo Coronary Lesions. 4- and 12-Month Angiographic Follow-Up and Final 5-Year Clinical Outcomes of the Prospective, Multicenter BioFreedom FIM Clinical Trial

Ricardo A. Costa, MD, PhD∗,†; Alexandre Abizaid, MD, PhD∗,†; Roxana Mehran, MD‡; Joachim Schofer, MD§; Gerhard C. Schuler, MD‖; Karl E. Hauptmann, MD¶; Marco A. Magalhães, MD†; Helen Parise, ScD‡; Eberhard Grube, MD#

Objectives: The purpose of this study was to evaluate the efficacy and long-term outcomes of a novel polymer/carrier-free drug-coated stent (DCS) in patients with de novo coronary lesions.

01 febrero 2016

JACC: CARDIOVASCULAR INTERVENTIONS. Long-Term Outcome of Incomplete Revascularization After Percutaneous Coronary Intervention in SCAAR (Swedish Coronary Angiography and Angioplasty Registry)

Kristina Hambraeus, MD, PhDa,b; Karin Jensevik, MScc; Bo Lagerqvist, MD, PhDb,c; Bertil Lindahl, MD, PhDb,c; Roland Carlsson, MD, PhDd; Ramin Farzaneh-Far, MDe; Thomas Kellerth, MDf; Elmir Omerovic, MD, PhDg; Gregg Stone, MD, PhDh; Christoph Varenhorst, MD, PhDb,c; Stefan James, MD, PhDb,c

Objectives: The aim of this study was to describe current practice regarding completeness of revascularization in patients with multivessel disease undergoing percutaneous coronary intervention (PCI) and to investigate the association of incomplete revascularization (IR) with death, repeat revascularization, and myocardial infarction (MI) in a large nationwide registry.

01 agosto 2015

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Coronary Interventions. Final 3-Year Outcome of a Randomized Trial Comparing Second-Generation Drug-Eluting Stents Using Either Biodegradable Polymer or Durable Polymer. NOBORI Biolimus-Eluting Versus XIENCE/PROMUS Everolimus-Eluting Stent Trial

Masahiro Natsuaki, MD, Ken Kozuma, MD, Takeshi Morimoto, MD, Kazushige Kadota, MD, Toshiya Muramatsu, MD, Yoshihisa Nakagawa, MD, Takashi Akasaka, MD, Keiichi Igarashi, MD, Kengo Tanabe, MD, Yoshihiro Morino, MD, Tetsuya Ishikawa, MD, Hideo Nishikawa, MD, Masaki Awata, MD, Mitsuru Abe, MD, Hisayuki Okada, MD, Yoshiki Takatsu, MD, Nobuhiko Ogata, MD, Kazuo Kimura, MD, Kazushi Urasawa, MD, Yasuhiro Tarutani, MD, Nobuo Shiode, MD and Takeshi Kimura, MD

Background: There is a paucity of data reporting the clinical outcomes of biodegradable polymer biolimus-eluting stent (BP-BES) compared with durable polymer everolimus-eluting stent (DP-EES) beyond 1 year after stent implantation when the polymer is fully degraded.

01 agosto 2015

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Coronary Interventions. Fixed and Modifiable Correlates of Drug-Eluting Stent Thrombosis From a Large All-Comers Registry. Insights From ADAPT-DES

Bruce R. Brodie, MD, Ankit Garg, MD, Thomas D. Stuckey, MD, Ajay J. Kirtane, MD, SM, Bernhard Witzenbichler, MD, Akiko Maehara, MD, Giora Weisz, MD, Michael J. Rinaldi, MD, Franz-Josef Neumann, MD, D. Christopher Metzger, MD, Roxana Mehran, MD, Rupa Parvataneni, MS and Gregg W. Stone, MD

Background: Previous studies evaluating correlates of stent thrombosis (ST) have included mostly patients with bare metal stents and early-generation drug-eluting stents (DES) and have not systematically evaluated the role of intravascular ultrasound–guided stenting and high platelet reactivity on clopidogrel. The purpose of this study was to evaluate the frequency and correlates of ST in patients receiving DES, specifically examining the impact of risk factors modifiable by physician and patient behavior.

01 agosto 2015

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Structural Heart Disease. Procedural Results and Clinical Outcomes of Transcatheter Aortic Valve Implantation in Switzerland. An Observational Cohort Study of Sapien 3 Versus Sapien XT Transcatheter Heart Valves

Ronald K Binder, MD*, Stefan Stortecky, MD*, Dik Heg, PhD, David Tueller, MD, Raban Jeger, MD, Stefan Toggweiler, MD, Giovanni Pedrazzini, MD, Franz W Amann, MD, Enrico Ferrari, MD, Stephane Noble, MD, Fabian Nietlispach, MD, PhD, Francesco Maisano, MD, Lorenz Räber, MD, PhD, Marco Roffi, MD, Jürg Grünenfelder, MD, Peter Jüni, MD, Christoph Huber, MD, Stephan Windecker, MD and Peter Wenaweser, MD

Background: New generation transcatheter heart valves (THV) may improve clinical outcomes of transcatheter aortic valve implantation

01 agosto 2015

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Coronary Physiologic Assessment and Imaging, Integrated Physiologic Assessment of Ischemic Heart Disease in Real-World Practice Using Index of Microcirculatory Resistance and Fractional Flow Reserve. Insights From the International Index of Microcirculatory Resistance Registry

Joo Myung Lee, MD, MPH, Jamie Layland, MBCHB, Ji-Hyun Jung, MD, Hyun-Jung Lee, MD, Mauro Echavarria-Pinto, MD, Stuart Watkins, MBChB, MD, Andy S. Yong, MBBS, PhD, Joon-Hyung Doh, MD, PhD, Chang-Wook Nam, MD, PhD, Eun-Seok Shin, MD, PhD, Bon-Kwon Koo, MD, PhD, Martin K. Ng, MBBS, PhD, Javier Escaned, MD, PhD, William F. Fearon, MD and Keith G. Oldroyd, MBChB

Background: The index of microcirculatory resistance (IMR) is a quantitative and specific index for coronary microcirculation. However, the distribution and determinants of IMR have not been fully investigated in patients with ischemic heart disease (IHD).

01 octubre 2015

AMERICAN HEART JOURNAL. Contemporary use of platelet function and pharmacogenomic testing among patients with acute myocardial infarction undergoing percutaneous coronary intervention in the United States

Tracy Y. Wang, MD, MHS, MS, Timothy D. Henry, MD, Lisa A. McCoy, MS, Peter B. Berger, MD, David J. Cohen, MD, MSc, Mark B. Effron, MD, Marjorie Zettler, PhD, MPH, Brian A. Baker, PharmD, John C. Messenger, MD, Eric D. Peterson, MD, MPH

BackgroundQ: Although platelet function and pharmacogenomic testing have been studied in clinical trials, their adoption into contemporary practice is unknown.

01 octubre 2015

AMERICAN HEART JOURNAL. Incidence and consequence of major bleeding in primary percutaneous intervention for ST-elevation myocardial infarction in the era of radial access: an analysis of the international randomized Acute myocardial infarction Treated with primary angioplasty and intravenous enoxaparin Or unfractionated heparin to Lower ischemic and bleeding events at short- and Long-term follow-up trial

Cyril Pellaton, MD, Guillaume Cayla, MD, PhD, Johanne Silvain, MD, PhD, Uwe Zeymer, MD, PhD, Marc Cohen, MD, Patrick Goldstein, MD, Kurt Huber, MD, PhD, Charles Pollack Jr., MD, Mathieu Kerneis, MD, Jean-Philippe Collet, MD, PhD, Eric Vicaut, MD, PhD, Gilles Montalescot, MD, PhDl for the ATOLL Investigators

Aims: The aims of the study are to compare the outcome with and without major bleeding and to identify the independent correlates of major bleeding complications and mortality in patients described in the ATOLL study.